Literature DB >> 4075048

Primary presenile dementia: the use of the visual evoked potential as a diagnostic indicator.

G F Harding, C E Wright, A Orwin.   

Abstract

The use of the flash and pattern reversal visual evoked potential (VEP) in the diagnosis of primary presenile dementia was investigated. The results from 20 patients with primary presenile dementia were compared with those from a control group of normals of equivalent age and from a control group of 20 patients with cortical atrophy but no dementia. Presenile dementia caused a slowing of the major positive (P2) component of the VEP to flash stimulation. However, the VEP to pattern reversal stimulation (P100) was of normal latency. The difference between these two latencies characterises this unusual combination of results and is found to be a more specific diagnostic indicator of primary presenile dementia than the EEG or CT scan.

Entities:  

Mesh:

Year:  1985        PMID: 4075048     DOI: 10.1192/bjp.147.5.532

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials.

Authors:  A T Smith; F Early; G H Jones
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Visual evoked potentials and neopterin: biopterin ratios in urine show a high correlation in Alzheimer's disease.

Authors:  C G Hamon; R J Cattell; C E Wright; O Wychrij; J A Blair; G F Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

3.  Olfactory impairment in motor neuron disease: a pilot study.

Authors:  M Elian
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

4.  Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease.

Authors:  Robert Kromer; Nermin Serbecic; Lucrezia Hausner; Lutz Froelich; Sven C Beutelspacher
Journal:  Front Neurol       Date:  2013-12-16       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.